Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
6th
years
Home>>Products>>cas 9041-08-1 99% Heparin sodium powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile: +8615207100586

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 9041-08-1 99% Heparin sodium powder

CAS NO.9041-08-1

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,
Contact Supplier

Product Details

Keywords

  • Heparin sodium
  • Heparin sodium powder
  • 99% Heparin sodium

Quick Details

  • ProName: cas 9041-08-1 99% Heparin sodium pow...
  • CasNo: 9041-08-1
  • Molecular Formula: C15H22O5
  • Appearance: white
  • Application: Heparin sodium salt can be used for th...
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Month
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

cas 9041-08-1  99%  Heparin sodium powder 

Product Name:    Heparin sodium
CAS:    9041-08-1
MF:    (C12H16NS2Na3)20

 

Details

 cas 9041-08-1  99%  Heparin sodium powder

Product Name:    Heparin sodium
CAS:    9041-08-1
MF:    (C12H16NS2Na3)20 

 

 


Heparin sodium salt, used as an anticoagulant, is a mucopolysaccharide substance, is the sodium salt form of glucosamine sulfate extracted from the intestinal mucosa of pigs, cattle, and sheep. It is secreted by mast cells to be naturally presented the blood inside the human bodies. Heparin can prevent platelet aggregation and destruction, inhibit the conversion from fibrinogen to fibrin monomers, inhibit the formation of thromboplastin and fight against the pre-formed thromboplastin, and also prevent the conversion of prothrombin to thrombin and counteract the antithrombin.

Heparin sodium salt can delay or prevent blood coagulation in vitro and in vivo. Its mechanism of action is very complicated which involves many processes of coagulation process. Its role is to: 1. inhibit the formation and function of thromboplastin, thus preventing the conversion of prothrombin into thrombin; 2. Inhibit the thrombin and other coagulation factors at relative high concentrations, preventing the conversion of fibrinogen to fibrous proteins; 3. prevent platelet aggregation and destruction. In addition, the anticoagulant effect of Heparin sodium salt is still related to the negatively charged sulfate inside its molecule. Positively charged alkaline substance such as protamine or toluidine blue can all neutralize its negative charge, thus inhibiting its anticoagulant effect. Because heparin can be activated in vivo and release lipoprotein lipase, hydrolyzing the triglycerides and low-density lipoprotein in chylomicrons, so it also has a lipid-lowering effect.

Heparin sodium salt can be used for the treatment of acute thromboembolic disease and disseminated intravascular coagulation (DIC). In recent years, it was found that heparin has an effect on blood lipid clearance. Intravenous or deep intramuscular injection (or subcutaneous) for 5,000 to 10,000 units per time is suitable. Heparin sodium salt has a low toxicity with spontaneous bleeding tendency as the major danger of the excessive use of heparin. Oral administration is invalid. Administration by injection is demanded. Intramuscular or subcutaneous injection is highly irritating with allergic reactions occur sometimes. Excess amount can even cause cardiac arrest; occasionally a transient hair loss and diarrhea occurs. In addition, it can also cause spontaneous fractures. Long-term use can sometimes cause thrombosis which may be the consequence of anticoagulation enzyme-III depletion.